Latest news

• IBM plans Watson-powered 'diabetes advisor'

  The collaboration will marry IBM's Watson supercomputer with the vast repository of clinical and research data held by the ADA. ... Announcing the tie-up at the ADA's annual scientific meeting earlier this month, IBM and the ADA also outlined their plans

• Rivals look to put pressure on Sanofi's Lantus

  The American Diabetes Association's (ADA) Scientific Sessions meeting in Boston this weekend saw several of Sanofi's rivals claim clinical benefits over its blockbuster Lantus (insulin glargine). ... of patients reaching the ADA's target of HbA1c of less

• Relief as study finds no cardiovascular risk with Januvia

  The data will be scrutinised further when presented at the American Diabetes Association (ADA) meeting in Boston in June, but analysts suggested the results could help Januvia consolidate its position as

• AZ and Takeda drugs should carry heart failure warning

  With that in mind, attention is fixed on the forthcoming results from the TECOS trial of Januvia, which are due to be presented at the American Diabetes Association (ADA) meeting in

• AZ's Onglyza may increase mortality, says FDA

  AZ's Onglyza (saxagliptin) and Kombiglyze (saxagliptin plus metformin) will come under scrutiny at the meeting along with a similar drug Nesina (alogliptin) from Takeda. ... TECOS results are due to be presented at the American Diabetes Association (ADA)